Engage Bio developed a platform technology that enables non-viral delivery of DNA to cells. The acquisition is the latest in a series of Eli Lilly deals that expand the pharmaceutical company’s pipeline and capabilities in genetic medicines.
Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnology with electronics comes with on-board sensors that enable clinicians to monitor and control an implant’s drug production process.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Denali Therapeutics’ Avlayah received FDA approval for treating Hunter syndrome, a rare neurological disorder. The biologic medicine uses Denali’s proprietary drug delivery technology to cross the protective blood-brain barrier.
Vivtex’s technology uses AI and high throughput screening to identify the combinations of drug ingredients that can deliver peptides through gastrointestinal tissue. Besides Novo Nordisk, the MIT spinout’s partners include Astellas Pharma, Equillium, and Orbis Medicines.
A Johnson & Johnson cancer treatment that can spare certain bladder cancer patients from the radical step of surgical removal of the organ now has FDA approval. J&J’s drug/device combination product, Inlexzo, came from the 2019 acquisition of Taris Biomedical.
Instead of an engineered peptide to activate gut receptors to trigger metabolic effects, Syntis’s technology forms a coating in intestines that has the effect of redirecting nutrients, mimicking an effect of gastric bypass surgery. In other obesity medicine news, Protagonist Therapeutics revealed a drug candidate that puts it in competition with Novo Nordisk and Eli Lilly, among others.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Navigating fertility treatment is stressful. Many patients face hurdles when accessing fertility drugs, but here you will find the best pharmacies for affordable fertility drug delivery in the U.S.
Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, permitting longer dosing intervals. Lilly plans to apply the technology to its metabolic medicines; the deal follows a similar move Novo Nordisk starting an alliance with Ascendis.
GSK is licensing an ABL Bio technology that yields bispecific antibodies engineered to leverage a certain transmembrane receptor to cross the blood-brain barrier to treat neurodegeneration. GSK is already partnered with Alector, which has monoclonal antibodies in clinical development for Alzheimer’s disease.
For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.
Halozyme views its drug delivery technology for biologic medicines as complementary to Evotec’s biologic drug manufacturing capabilities. But according to Halozyme, Evotec was unwilling to engage in any merger discussions.
Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.
Demand for alternative drug delivery methods has the potential to reshape therapeutic markets and improve clinical outcomes. New innovations, especially oral alternatives, are poised to drive broad changes across the entire sector.
Surge Therapeutics' hydrogel is engineered to deliver a cancer immunotherapy. Rather than replace surgery, CEO Michael Goldberg says the hydrogel could supplement this standard of care for solid tumors. The startup's Series A financing will support the technology's first test in humans.
Vector BioPharma has launched from the biotech startup incubator of Versant Ventures, which is backing the company with a $30 million Series A financing. Vector is developing virus-like particles with the capability to deliver large payloads of genetic medicines to a wide range of tissues.